Methods for determining total body skeletal muscle mass
US-9737260-B2 · Aug 22, 2017 · US
US2025277800A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2025277800-A1 |
| Application number | US-202418592917-A |
| Country | US |
| Kind code | A1 |
| Filing date | Mar 1, 2024 |
| Priority date | Mar 1, 2024 |
| Publication date | Sep 4, 2025 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Aptamers and methods for detecting a target molecule/analyte in a sample are disclosed herein. The aptamer can include a single-stranded deoxyribonucleic acid (DNA) strand that includes an oligonucleotide sequence with bases identical at least about 60% to TAATTGTGGTTCGTGTAAA (SEQ ID NO: 1). The aptamer can be configured to bind the target molecule/analyte with a dissociation constant between about 10−9 and about 10−3 M.
Opening claim text (preview).
What is claimed is: 1 . An aptamer for detecting a target molecule/analyte in a sample comprising a single-stranded deoxyribonucleic acid (DNA) strand that includes an oligonucleotide sequence with bases identical at least about 60% to TAATTGTGGTTCGTGTAAA (SEQ ID NO: 1), wherein the aptamer is configured to bind the target molecule/analyte with a dissociation constant between about 10 −9 and about 10 −3 M. 2 . The aptamer of claim 1 , wherein the target molecule/analyte is creatinine. 3 . The aptamer of claim 1 , wherein the single-stranded DNA strand comprises at least about fifteen bases. 4 . The aptamer of claim 1 , wherein the aptamer comprises at least one modification. 5 . The aptamer of claim 4 , wherein the at least one modification is selected from the group consisting of atom substitution, neutralization of negative charges, introduction of positive charges, and combinations thereof. 6 . The aptamer of claim 4 , wherein the at least one modification is a modified base, wherein the modified base is selected from the group consisting of a ribonucleic acid (RNA), a modified RNA, a modified DNA, a peptide nucleic acid (PNA), and combinations thereof. 7 . The aptamer of claim 1 , wherein the sample comprises blood, serum, effluent, saliva, sweat, tears, or combinations thereof. 8 . The aptamer of claim 1 , wherein the aptamer comprises a functional group, wherein the functional group comprises thiols, phosphothiols, carboxyl, amines, carbonyls, aldehydes, alkynes, azides, alkenes, strained alkenes, tetrazines, and/or products thereof. 9 . The aptamer of claim 1 , wherein the aptamer is a stem-loop aptamer that includes a capture region and a stem region, wherein the stem region is configured to be positioned to transform a second conformation into a stem-loop structure of the aptamer, or stem-loop structure into a second conformation when the oligonucleotide sequence binds to the target molecule/analyte. 10 . The aptamer of claim 1 , wherein the aptamer is modified or configured to be immobilized to a substrate for sensing the target molecule/analyte. 11 . The aptamer of claim 9 , wherein the stem-loop structure is modified to move away from the substrate upon binding to the target molecule/analyte. 12 . The aptamer of claim 9 , wherein the stem-loop structure is modified to approach to the substrate upon binding to the target molecule/analyte. 13 . The aptamer of claim 1 , wherein the aptamer is configured to be incorporated into a sensor device, wherein the sensor device comprises a field-effect transistor and the aptamer. 14 . The aptamer of claim 1 , wherein the aptamer is configured to be incorporated into a sensor device, wherein the sensor device comprises a gold substrate and the aptamer. 15 . The aptamer of claim 1 , wherein the aptamer is configured to be incorporated into a sensor device, wherein the sensor device comprises a fiber-optical cable and the aptamer. 16 . The aptamer of claim 1 , wherein the aptamer is configured to be incorporated into a sensor device, wherein the sensor device comprises a quartz surface and the aptamer. 17 . The aptamer of claim 1 , wherein the aptamer is configured to the target molecule/analyte without being freely diffused. 18 . The aptamer of claim 13 , wherein the sensor device comprises a freely diffusing molecular with a molecular weight between about 1,000 D and about 1,000,000 D. 19 . The aptamer of claim 1 , wherein the aptamer is attached to a fluorophore, a quencher, an enzyme, a redox dye, or combinations thereof. 20 . The aptamer of claim 1 , wherein the sample is a diluted sample, wherein the diluted sample is a sample diluted up to about 1%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000% with a solution. 21 . The aptamer of claim 1 , wherein the sample is a non-diluted sample. 22 . A method for detecting a target molecule/analyte in a sample, comprising: contacting at least a portion of the sample with effective amounts of an aptamer, wherein the aptamer comprises a single-stranded deoxyribonucleic acid (DNA) strand that includes an oligonucleotide sequence with bases identical at least about 60% to TAATTGTGGTTCGTGTAAA (SEQ ID NO: 1), wherein the aptamer is configured to bind the target molecule/analyte with a dissociation constant between about 10 −9 and about 10 −3 M, detecting a change after the contacting. 23 . The method of claim 22 , wherein the change comprises a change of conductance, fluorescence, and/or any electrochemical readouts. 24 . The method of claim 22 , wherein the target molecule/analyte is creatinine. 25 . The method of claim 22 , wherein the sample comprises blood, plasma, serum, effluent, saliva, sweat, tears, or combinations thereof. 26 . The method of claim 22 , wherein the aptamer is a stem-loop aptamer that includes a capture region and a stem region, wherein the stem region is configured to be positioned to transform a stem-loop structure of the aptamer to a second conformation when the oligonucleotide sequence binds to the target molecule/analyte. 27 . The method of claim 22 , wherein the aptamer is configured to be immobilized to a substrate for sensing the target molecule/analyte. 28 . The method of claim 27 , wherein the substrate comprises gold and/or quartz. 29 . The method of claim 26 , wherein the stem-loop structure is modified to move away from the substrate upon binding to the target molecule/analyte so the conductance of the substrate changes. 30 . The method of claim 26 , wherein the stem-loop structure is modified to approach to the substrate upon binding to the target molecule/analyte so the conductance of the substrate changes. 31 . The method of claim 22 , wherein the aptamer is attached to a fluorophore, a quencher, an enzyme, a redox dye, or combinations thereof. 32 . The method of claim 22 , wherein the sample is a diluted sample, wherein the sample is a diluted sample, wherein the diluted sample is a sample diluted up to about 1%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000% with a solution. 33 . The method of claim 22 , wherein the sample is a non-diluted sample. 34 . The method of claim 22 , further comprising diagnosing a kidney disease based on the detected level of creatinine in the sample, and providing a subject with a treatment based on the detected level of creatinine in the sample. 35 . The method of claim 34 , wherein a level of the treatment is enhanced with an increased creatinine level detected by the aptamer. 36 . The method of claim 34 , wherein a level of the treatment is lowered with a decreased creatinine level detected by the aptamer. 37 . The method of claim 22 , further comprising sensing the target molecule/analyte at a predetermined frequency. 38 . The method of claim 37 , the predetermined frequency comprises once every hour, once every ten minutes, once every minute, once every second, or any predetermined period in between.
for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites · CPC title
Aptamers · CPC title
Stem-loop; Hairpin · CPC title
Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers} · CPC title
involving creatine or creatinine · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.